02674nam a22003617a 4500
220926s20222022 xxu||||| |||| 00| 0 eng d
2072-6694
10.3390/cancers14112596 [doi]
cancers14112596 [pii]
PMC9179451 [pmc]
Ovid MEDLINE(R)
35681574
BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer.
Cancers. 14(11), 2022 May 24.
Cancers (Basel). 14(11), 2022 May 24.
Cancers
2022
FY2022
2022 May 24
epublish
PubMed-not-MEDLINE
2022-07-06
BERENICE (NCT02132949) assessed the cardiac safety of the neoadjuvant-adjuvant pertuzumab-trastuzumab-based therapy for high-risk, HER2-positive early breast cancer (EBC). We describe key secondary objectives at final analysis. Eligible patients received dose-dense doxorubicin and cyclophosphamide q2w x 4 paclitaxel qw x 12 (Cohort A) or 5-fluorouracil, epirubicin, cyclophosphamide q3w x 4 docetaxel q3w x 4 (B) as per physician's choice. Pertuzumab-trastuzumab (q3w) was initiated from the taxane start and continued post-surgery to complete 1 year. Median follow-up: 64.5 months. There were no new cardiac issues and a low incidence of Class III/IV heart failure (Cohort B only: one patient (0.5%) in the adjuvant and treatment-free follow-up (TFFU) periods). Fourteen patients (7.7%) had LVEF declines of >=10% points from baseline to <50% in Cohort A, as did 20 (10.5%) in B during the adjuvant period (12 (6.2%) in A and 7 (3.6%) in B during TFFU). The five-year event-free survival rates in Cohorts A and B were 90.8% (95% CI: 86.5, 95.2) and 89.2% (84.8, 93.6), respectively. The five-year overall survival rates were 96.1% (95% CI: 93.3, 98.9) and 93.8% (90.3, 97.2), respectively. The final analysis of BERENICE further supports pertuzumab-trastuzumab-based therapies as standard of care for high-risk, HER2-positive EBC.
English
IN PROCESS -- NOT YET INDEXED
Associate Dean for Research Development
MedStar Health
Journal Article
Swain, Sandra M
Colomer R, Dadswell K, Dang C, de Haas SL, de la Cruz-Merino L, Delaloge S, Eiger D, Ewer MS, Ferrero JM, Restuccia E, Sarkar S, Swain SM, Verrill M, Werner TL
https://dx.doi.org/10.3390/cancers14112596
https://dx.doi.org/10.3390/cancers14112596
ART
Article
0
0
0
0
Article
authcat
authcat
2022-07-06
0
35681574
35681574
2022-07-06
2022-07-06
ART
418
418